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I. INTRODUCTION
Biobanking is the organized collection of DNA and
accompanying medical information from human populations.' I
will begin this presentation with an attempt to make biobanking as
tangible as possible through an illustrative case study and
discussion of the endeavor in the context of contemporary genetics
research and development ("R&D") to improve human health.
Second, I will place biobanking in relation to centuries of practice
collecting human biological materials and using them in research,
survey the associated ethical, legal, and social issues, and then
address the additional dimension of considerations and
complications introduced by biobanking. Third, I will touch upon
the possibility of drawing from biotechnology technology transfer
and development experience to introduce incentives for desirable
and responsible biobanking. As I will explain, this challenge is
fourfold-to think broadly and creatively (1) to identify objectives
that might be accomplished through biobanking, and reach beyond
the obvious when doing so, (2) to craft possible arrangements that
harness commercial incentives to advance biobanking that realize
at least some of those objectives, (3) to make those arrangements
achievable, and (4) to thoughtfully contemplate ethical, legal, and
social implications and remain attentive to human subject
protections while doing so. The latter must check and shape the
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former, for this exercise instills a conscience in technology transfer
and development especially essential for undertakings as
complicated as biobanking.
II. BIOBANKING IN THE CONTEXT OF CONTEMPORARY GENOMICS
R&D
With the map of the human genome in hand,2 we now hold
three billion decoded base pairs and face the task of making
medical meaning out of these As, Cs, Gs, and Ts.3 You have heard
a lot about that already this morning.4 Just as a conceptual point of
reference, if you were to take each of these letters and make them
the size of standard letters and text, you would end up with a string
of As, Cs, Gs, and Ts spanning from Portland, Oregon to Chicago,
Illinois.5 We are finding that variations in even single letters may
hold some medical meaning.6  How do we do all of this?
Bioinformatics.7
2. For information about the genome map and the Human Genome Project
(HGP), visit the National Human Genome Research Institute (HGRI) hompage,
http://www.genome.gov.
3. A "rough draft" map of the human genome was announced on June 26,
2000, and a "first draft" was completed in 2003. See Michael J. Malinowski,
Law, Policy, and Market Implications of Genetic Profiling in Drug
Development, 2 Hous. J. Health L. & Pol'y 31, 31 n.1 (2002) [hereinafter
Malinowski, Market Implications].
4. J. Michael McGinnis, Population Health and the Influence of Medical
and Scientific Advances, 66 La. L. Rev. (Special Issue) 9 (2006); Paula W.
Yoon, Risk Prediction for Common Diseases, 66 La. L. Rev. (Special Issue) 33
(2006).
5. Malinowski, Market Implications, supra note 3, at 41 n.6 1.
6. See generally Robert Wells, Intellectual Property/Ownership Issues, 66
La. L. Rev. (Special Issue) 69 (2006). See Lars Noah, The Coming
Pharmacogenomics Revolution: Tailoring Drugs to Fit Patients' Genetic
Profiles, 43 Jurimetrics J. 1, 7-11 (2002).
7. In the simplest terms, bioinformatics is the integration of biology and
information technology to identify gene and protein structure and function,
usually with the ultimate objective of discovering drug targets or otherwise
impacting human health. See David E. Winickoff, Governing Population
Genomics: Law, Bioethics, and Biopolitics in Three Case Studies, 43 Jurimetrics
J. 187, 189 (2003). See generally Wells, supra note 6. See also Michael J.
Malinowski, Separating Predictive Genetic Testing from Snake Oil: Regulation,
Liabilities, and Lost Opportunities, 41 Jurimetrics J. 23, 26 (2000) [hereinafter
Malinowksi, Snake Oil].
If you look back at 1990, the HGP presupposed, either naively
or in a Pollyanna manner, that the effort was doable-that the
necessary enabling technologies would come and within the HGP's
time frame. HGP would have been an enormous "white elephant,"
and definitely would have taken a lot longer than it did, without the
advent of a surge in Information Technology (IT) capabilities
during the 1990s. 8 And those capabilities continue to flow.9
Today, ongoing progress in IT, at least to some extent, fuels
virtually all efforts to make medical sense out of the human
genome map. We know that we grossly underestimated the
complexity of the human genome-a compilation of
approximately just 30,000 active genes, rather than the 100,000-
150,000 estimated throughout the mapping process.'
0
Reminiscent of Galileo pointing his telescope into the sky and
discovering celestial "new lands," ' 1 contemporary scientists are
using bioinformatics to peer into the human genome. They are
beginning to truly comprehend the extent to which the human
genome is a universe that encompasses voluminous multitasking
and innumerable layers of dynamic intricacy. Consequently, the
science community and pharmaceutical and biotechnology sectors
are more fully appreciating, and realizing, the difficulty of crafting
market-scale medical applications from genetic knowledge.' 2 Yet,
bioinformatics is providing a means to move forward. Given IT
capabilities, the pace of progress of biomedical R&D increasingly
8. "In 1997, HGP was half-way through its 15-year duration and 90% of
the project's funding had been spent just to sequence accurately 2.68% of the
human genome." Malinowski, Snake Oil, supra note 7, at 26.
9. See generally Wells, supra note 6.
10. See generally McGinnis, supra note 4. Keep in mind that, while the
number of genes has fallen by more than two-thirds, human diversity has
remained constant-meaning that all measurable human difference is
attributable to a much smaller number of genes than previously anticipated. Cf
id.
11. Galileo's findings also ran contrary to prevailing notions in science:
It was inevitable, though, that one night the moon would catch his
attention, and Galileo would think of pointing his telescope at its bright
disk. From that moment, Galileo went on to discover new "lands" in
the sky above. The craggy features of the moon surprised him, the
increased number of stars he saw amazed him, but his most astounding
discovery was when he realized four moons were orbiting Jupiter!
Galileo published this incredible find, and the news rocked the world,
because at that time people believed that everything in the sky orbited
the Earth.
http://www.crystalinks.com/telescopes.html.
12. Janet Woodcock, FDA Policy on Pharmacogenomic Data in Drug
Development, 66 La. L. Rev. (Special Issue) 91 (2006).
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depends upon access to human biological samples and medical
information.' 3 Contemporary genomics is centering on this need,
which is a trend that I believe will increase over many years in
conjunction with the continued advancement of IT.
It is important to conceptually understand the scientific
methodologies associated with any biobanking case study, for
those tend to have a significant impact on how the banks are
established and utilized. Keep in mind that there are all kinds of
popular scientific methodologies in contemporary genetics R&D
that could benefit from access to biobanks and, admittedly, a lot of
people have reservations about the primary methodology
associated with this case study that I now will address.14 That said,
imagine that scientists could comb through the DNA and medical
histories of whole populations of people biologically related,
differentiate the sick from the healthy, and identify the
predominant diseases causing ill health in the study population.
Depending upon how meaningful the genetic common
denominator is among members of the study population,
presumably the scientists would have a better chance of figuring
out which genes are involved in those targeted diseases. If the
diseases also are prevalent in the general population, presumably
that genetic knowledge would carry-over into broad human health
use-the "big picture" goal of genomics.15 So, where can today's
scientists go to undertake this kind of research?
13. See generally Noah, supra note 6.
14. Henry T. Greely, Population Participation and Other Factors that
Impact the Compilation and the Utility of Resulting Databases, La. L. Rev.
(Special Issue) 79 (2006).
15. A consideration beyond the scope of this discussion is the fact that,
traditionally, diseases often have been classified based upon patient symptoms.
Contemporary genetics is breaking down some of these traditional
classifications by distinguishing genetic origins. For example, "breast cancer"
now is known to encompass Her-2-neu related breast cancer, BRCA1-BRCA2
related breast cancer, and others. The Baylor College of Medicine has even
established online-searching capabilities for breast cancer genes. See Baylor
College of Medicine, Breast Cancer Gene Database, http://condor.bcm
.tmc.edu/ermb/bcgd/bcgd.html. Consequently, although a disease prevalent
among contributors to a particular biobank may appear to be the same disease
prevalent in the general population, the diseases may prove genetically
distinguishable based upon characteristics idiosyncratic to the group under
study. The methodology for most large-scale biobanking undertaken thus far
has been to exaggerate genetic similarity among contributors in order to isolate
"disease genes." See infra notes 16 and 17 and accompanying text. However,
biobanking is also being undertaken based upon the prevalence of disease rather
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Well, one place is a little island nation in the
North Atlantic, Iceland. In many ways, Iceland is
the perfect place to look for genes that cause
diseases. It's got a tiny population, only about
280,000 people, and virtually all of them are
descended from the original settlers, Vikings, who
came here over a thousand years ago.
If you drive around this country, you will have
great difficulties finding any evidence of that
dynamic culture that was there for all these 1100
years. There are no great buildings; there are no
monuments. But one thing Iceland does have is a
fantastic written history, including almost
everybody's family tree. And now it's all in a giant
database. Just punch in a Social Security number
and there they are, all your ancestors, right back to
the original Viking.16
Now, I would like to present you with a disease study
application of this methodology, still drawing from Iceland. The
disease is osteoarthritis, and the case study highlights how laws
were changed to create this biobank, the role of commercial
interests, what the medical community's response was, and a broad
sampling of ethical, legal, and social implications raised through
application. So, let us return to Iceland:
NARRATOR: Stefenson is a Harvard-trained
scientist who saw the potential goldmine that might
be hidden in Iceland's genetic history. He set up a
company called deCODE Genetics to combine age-
old family trees with state-of-the-art DNA analysis
and computer technology, and systematically hunt
down the genes that cause disease.
STEFENSON: Our idea was to try to bring
together as much data on health care as possible, as
than biological ties. Such an effort has been orchestrated by a commercial
biobanker, Ardais Corporation, and has drawn together Harvard-affiliated Beth
Israel Hospital, Duke University Medical Center, Maine Medical Center, and the
University of Chicago. See infra notes 22 and 69 and accompanying text.
16. Video: Nova, Cracking the Code of Life (2002) (video on file with
author), available at http://www.pbs.org/wgbh/nova/genome/program.html.
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much data on genetics as possible, and the
genealogy, and simply use the informatics tools to
help us discover new knowledge, discover new
ways to diagnose, treat and prevent diseases.
NARRATOR: One of deCODE's first projects
was to look for the genes that might cause
osteoarthritis. Mrs. Reinheir Magnus's daughter
had the debilitating disease most of her life.
MRS. MAGNUS'S DAUGHTER: The first
symptoms appeared when I was 12. And by the age
of 14, my knees hurt very badly. No one really paid
any attention; that's just the way it was. But by the
age of 39, I'd had enough, so I went to a doctor.
NARRATOR: Mrs. Magnus's daughter was
never alone in her suffering. She is one of
seventeen children. Eleven of them were so
stricken with arthritis they had to have their hips
replaced. This was exactly the kind of family that
deCODE was looking for. They got Mrs. Magnus's
daughter and other members of her family to donate
blood samples for DNA analysis and to find more
of her relatives--people she had never met.
deCODE just entered her Social Security number
into their giant database, and there they were. But
which of these people have arthritis? To find out,
Stefenson asked the government of Iceland to give
his company exclusive access to the entire country's
medical records. In exchange, deCODE would pay
$1 million dollars a year, plus a share of any profits.
That way, deCODE could link everything in their
computers, DNA, health records, and family trees.
This idea was probably more debated than any other
issue in the history of the Republic. On the eve of
the Parliamentary vote on the bill, there was an
opinion poll taken which showed that 75 percent of
those who took a stand on the issue supported the
passage of the bill; 25 percent were against it.
Among that 25 percent against the plan were most
of Iceland's doctors.
AN ICELANDIC DOCTOR: I first thought
there was something fundamentally wrong in all of
[Vol. 66
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this, you know. They do know everything about
you, not only about your medical history and about
your medical past, but they now do have your
genes, the DNA. They know about your future,
something about your children, about your elders.
We find ourselves powerless because there is really
nothing we can do because the one who takes the
responsibility is the management of the health
center. If they give away this information from the
medical records, they get money, and everybody
needs money. Healthcare really needs money.
NARRATOR: So what really is the problem
here? Well, let us take a hypothetical example. I
am going to make all this up. Let us pretend these
are medical records of an average person. And
we'll suppose that right here I see an HIV test, and
then over here is medication for anxiety after what
appears to be a messy divorce, and over here a
parent who died of Alzheimer's. Now, this is all
stuff that could happen to anybody, but do you want
it all in some central computer bank, and do you
want it linked in the same computer to all your
relatives, and to your own personal DNA file, and
should anybody have the right to go on a fishing
expedition through your medical history and your
DNA? Well, it may be frightening, but it also might
work. deCODE claims it's discovered several
genes that may contribute to osteoarthritis. So this
approach, combining family trees, medical records
and DNA, could lead to better drugs, or to cures for
a whole range of diseases. To have all of the data in
one place so you can use some modem equipment
to juxtapose the bits and pieces, look for the best fit.
It is an absolutely fascinating possibility. Stefenson
says no one's forced to do this, and there are
elaborate privacy protections in place. No names
are used and Social Security numbers are encoded.
He also argues that the DNA part of the database is
voluntary.
STEFENSAN: The healthcare database only
contains healthcare information. We can cross-
reference it with DNA information, but only from
those individuals who have been willing to give us
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blood, allowed us to isolate DNA, genotype it, and
cross-referencing it with the database, only from
those who have deliberately taken that risk. So it's
not imposed on anyone, and no one who is scared of
it, no one who is really afraid of it, should come and
give us blood.
NARRATOR: DNA databases are popping up
all over the world, including the U.S. They all have
rules for protecting privacy, but they still make
ethicists nervous.
In fact, the world is biobanking.18 Nine or so countries already
have vested or announced vesting-for example, the United
Kingdom has announced its intention to compile the world's
largest biobank to date. 19 Domestically, the state of Utah has been
debating for years whether it should biobank. 20  Academic
institutions, hospitals, disease groups, and commercial entities
have undertaken a range of biobanking initiatives, often in
collaboration. 21 Ardais, a Boston-area company, is working with a
number of hospitals domestically to do biobanking at an intense,
application level.22 Some of these efforts already have failed, but
biobanking is real, underway, and increasing rapidly.
III. BIOBANKING IN THE CONTEXT OF THE U.S. LEGACY OF HUMAN
SAMPLE COLLECTION
17. Id. For more information about deCODE, including the studies
mentioned in this excerpt, visit the company's web site at
http://www.decode.com. For law-policy treatments of the deCODE case study
and related controversies, see Henry T. Greely, Iceland's Plan for Genomics
Research: Facts and Implications, 40 Jurimetrics J. 153 (2000). See also
Winickoff, supra note 7.
18. See generally Regulation of Biobanks, supra note 1. See also
Winickoff, supra note 7.
19. Michael J. Malinowski, Technology Transfer in BioBanking: Credits,
Debits, and Population Health Futures, 33 J.L. Med. & Ethics 54, 56-57 (2005)
[hereinafter Malinowski, Population Health Futures].
20. See id. at 57; Kirk Johnson, By Accident, Utah Is Proving An Ideal
Genetic Laboratory, N.Y. Times, Jul. 31, 2004, at Al.
21. Malinowski, Population Health Futures, supra note 19, at 56-57.
22. Id. at 57 n.68. See generally The Ardais Corporation Home Page,
http://www.ardais.com. See infra note 69 and accompanying text.
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If we take what we heard this morning to heart, relative to
familiar norms, human biological materials will generate
unprecedented amounts of information in the years to come,
thereby creating equally unprecedented demand for access to them
for biomedical R&D. Nevertheless, taking a moment to look
back, biobanking is not some bolt of lightening. Rather,
biobanking is a contemporary extension of a practice we have been
doing for over a century, which is aggressively collecting human
biological matter and putting those samples together in repositories
to create the means to do medical research.24 Most of the samples
added to U.S. repositories prior to 2000 were gathered with
minimal or no consent to research use, often because those uses
were not fully defined or appreciated at the time of collection.
25
23. Cf McGinnis, supra note 4; Yoon, supra note 4.
24. See Allen Buchanan, An Ethical Framework for Biological Samples
Policy, in Research Involving Human Biological Materials: Ethical Issues and
Policy Guidance, Volume II Commissioned Papers B-1 (National Bioethics
Advisory Commission, Jan. 2000), available at http://www.georgetown.
edu/research/nrcbl/nbac/hbmlI.pdf; Elisa Eiseman, Stored Tissue Samples: An
Inventory of Sources in the United States, in Research Involving Human
Biological Materials: Ethical Issues and Policy Guidance, Volume II
Commissioned Papers D-1 (National Bioethics Advisory Commission, Jan.
2000), available at http://www.georgetown.edu/ research/nrcbl/nbac/hbmlI.pdf;
David Kom, Contribution of the Human Tissue Archive to the Advancement of
Medical Knowledge and the Public Health, in Research Involving Human
Biological Materials: Ethical Issues and Policy Guidance, Volume II
Commissioned Papers E-1 (National Bioethics Advisory Commission, Jan.
2000), available at http://www.georgetown.edu/ research/nrcbl/nbac/hbmll.pdf.
25. As Dr. Kom explained:
The samples were removed for medical reasons, under sparing consent
language that usually included a proviso for research and educational
uses, and were submitted to the pathology laboratory for routine
diagnostic evaluation, after which portions of the specimens were
permanently stored as part of the patient's medical record, in
accordance with sound medical practice and legal and accreditation
requirements. Although not specifically collected for research
purposes, these specimens have served as a rich and irreplaceable
source of materials for clinico-pathological investigations that have
provided over the past more than 100 years most of the vocabulary and
much of the intellectual foundation of modem medicine.
Kom, supra note 24, at E-23. Donor knowledge and sample identifiability are
almost as varied as the repositories themselves:
The individuals who are the sources of the samples are identified in
some cases, not in others. Some samples were gathered during
procedures (such as surgery) in which some form of informed consent
was attained, some were not. Even where there was informed consent
for the procedure that produced the sample, often there was no
2005]
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"Medical waste" and "donor abandonment" are fre9uently
offered as justifications for these unauthorized collections. The
resulting repositories have been grouped into the following
classifications: 27
Large tissue banks, repositories, and core facilities;
Materials collected as part of longitudinal studies;
Tailored collections for research studies requiring unique
tissue collections;
Pathology specimens initially collected for clinical
purposes;
Newborn screening tests accumulating in various
laboratory sites;
Forensic DNA banks (many established through federal
and state legislation);
Umbilical cord blood banks;
Organ banks;
Blood banks; and
Sperm, ova, and embryo banks.
The U.S. federal government has been an aggressive
collector-historically, the most aggressive collector-of human
biological samples.26' The Armed Forces Institute of Pathology
(AFIP) houses two of the world's largest tissue repositories: the
National Pathology Repository and the Department of Defense
(DoD) DNA Specimen Repository for Remains Identification. 29
And government collecting and financial support of other
collectors is ongoing and substantial. For example, the Center for
Disease Control and Prevention (CDC) has established a repository
known as NHANES that holds thousands of cell lines.30 Also, the
informed consent to the storage of the sample, nor to some or any
possible future uses of it after storage. In many, perhaps most cases,
individuals had no idea that their sample was being stored, nor any
inkling that it might be used for a variety of research purposes, by a
variety of individuals.
Buchanan, supra note 24, at B-3.
26. See Malinowski, Market Implications, supra note 3, at 46 n.93.
27. Eiseman, supra note 24, at D-38. For contact information for organ and
tissue banks on a state-by-state basis, see id. at Appendix 1, and the Internet site
for the New England Organ Bank, http://www.neob.org.
28. See generally Eiseman, supra note 24.
29. Id. at D-7, D-40.
30. See Testimony, Human Biological Materials (Mar. 1998), http://www.
georgetown.edu/research/nrcbl/nbac/transcripts/mar98/hbmr-spkrs.htm.
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National Institutes of Health (NIH) has and continues to
significantly fund tissue repositories and has been engaging in
biocommerce for years.
3 1
Throughout the last century, careful study of archived patient
tissue samples and medical records has proven the fundamental
means for medical progress.32 Pathology-the scientific study of
the causes, mechanisms, and natural history of diseases-
originated in Germany in the mid-nineteenth century.33  "[T]he
discipline of pathology has contributed essentially all of the
vocabulary and much of the intellectual foundation of
contemporary medicine. The development of this knowledge base
has come largely from the systematic clinico-pathologic study of
human tissue samples removed during the course of medical care.
.,3 Pathology is, in essence, a common denominator in the
study of disease, for
[a]ll new methods for the study of disease, whether they be
monoclonal antibodies, new molecular genetic
technologies, or others yet to come, ultimately must be
interpreted and validated with reference to known disease
entities and appropriate controls, and that process requires,
without exception, that the methods be developed and
evaluated with authenticated pathologic materials.
3
Intertwined, pathology and medicine have progressed together
and advanced in the direction of precision-meaning from
understanding disease expression at the whole organ and tissue
levels to understanding it at the subcellular, supramolecular, and
molecular levels. 36  Along the way, the coupling of these
31. Eiseman, supra note 24, at D-9. For example, in 2000, the National
Institute of Mental Health (NIMH) sold Merck, Pfizer, Millennium
Pharmaceuticals, and Sandozo access to interviews, clinical data, and DNA
samples from hundreds of families with Alzheimer's disease, schizophrenia, and
manic-depression. See Lori Andrews & Dorothy Nelkin, Body Bazaar: The
Market for Human Tissue in the Biotechnology Age 25-26 (2001) (addressing
realization of commercial value of this repository).
32. Kom, supra note 24, at E-23.
33. Id. at E-3.
34. Id.
35. Id. at E-4.
36. Id. at E-3. For examples that illustrate the contributions to the
advancement of medicine attributable to autopsy and surgical materials, see id.
at E-4 to E-23.
2005]
LOUISIANA LA W REVIEW
disciplines has birthed an impressive range of medical benefits
through the use of stored biological samples.
37
These accomplishments have been realized despite the fact
that, historically, there had been no centralized database to allow
researchers full information about, and access to, these vast
storages of human biological material. However, proliferation of
information technology in the 1990s inspired efforts to organize
these resources electronically. For example, the National Cancer
Institute (NCI) established an information database of breast
cancer resources to advance relevant research and promote
collaboration among basic, clinical and epidemiologic
researchers.38  Soon a trend emerged in favor of establishing
repositories tailored to specific research, including the NCI-
37. As highlighted by Professor Buchanan:
1) In the late 1960s, the study of samples of tissue from an unusual
tumor of the vagina led to the discovery that a nonsteroidal estrogen
hormone diethylstilbestrol (DES), then commonly given to women
during pregnancy, is carcinogenic. 2) During the same decade a series
of studies on tissue samples of precancerous lesions of the uterine
cervix led to the routine use of the Pap smear, which has played an
important role in the early diagnosis and more successful treatment of
this type of cancer. 3) Analysis of tissue from autopsies of persons in
certain occupations, such as chemical manufacturing and uranium
mining, has established causal links between exposure to environmental
substances and certain diseases, including a cancer of the liver known
as hepatic angiosarcome and cancer of the bronchial epithelium. 4)
The analysis of autopsied lung tissue from smokers played a major role
in establishing that smoking causes lung cancer, that the risk of cancer
increases with the duration of exposure to the chemicals contained in
cigarette smoke, and that precancerous changes in the bronchial
epithelium can be reversed by cessation of smoking. 5) In 1953,
autopsies of young American soldiers killed in the Korean conflict
revealed that atherosclerosis begins at a much earlier age than was
previously thought and that blockage of arteries can be far advanced in
the absence of symptoms; this research contributed to findings
concerning diet and exercise which have had a major public health
impact in this country, evidenced by a significant reduction in coronary
artery disease. In many instances, access to stored biological samples
collected over a long period has significant advantages over the
exclusive use of new research protocols. Especially when the disease
process under study takes place over years or even decades, studies that
rely only on newly collected tissue may be very costly and produce
results much less quickly than studies of stored samples.
Buchanan, supra note 24, at B- 13.
38. Eiseman, supra note 24, at D-41.
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NAPBC Breast Cancer Specimen System 39 and the NIH Women's
Health Initiative.4 °
The advent of disciplines such as genomics (the study of gene
expression and its impact on human health)41 and proteomics (the
study of protein function in human health) 4 at the close of the last
millennium have jolted pathology and human health into an era of
molecular and genetic medicine.43  Now, with the map of the
human genome in hand and with contemporary bioinformatics
capabilities, biobanking is a potential means to make medical sense
out of the human genome. What is getting interesting and difficult
is, in the age of federal privacy under the Health Insurance
Portability and Accountability Act ("HIPPA"),44 the Human
Genome Project,45 and the HapMap Project that you are going to
be hearing a lot more about over the next day or so, we are in a
very awkward place. There is a paradox here in that we are able to
generate much more information from a given sample than we ever
anticipated even just several years ago. And at the moment when
we can do that, we have a legitimization of long-standing privacy
concerns which tells us to go slow, to add some protections, and
yet the potential medical benefits have never been as significant.
So the temptation to go faster, to go furious, is very high.
Given this temptation and the U.S. legacy in human sample
46collection, responsible biobanking requires reflection on basic
ethical, legal, and social issues associated with sample collection
and use, and thoughtful identification and treatment of the more
39. As of 1996, the System contained more than 130,000 cases and 240,000
specimens. See id. at D-40, D-39 tbl.8.
40. As of 1996, the Initiative had collected 164,500 cases and more than
329,000 specimens. See id.
41. For a discussion of genomics from the perspective of science and
medicine, see McGinnis, supra note 4.
42. See generally Wells, supra note 6.
43. James D. Watson, DNA: The Secret of Life (2003). This new
dimension of precision is moving us closer towards pharmacogenetics, meaning
health care tailored to one's genetic idiosyncracies and, ultimately, personally
customized pharmaceuticals. Noah, supra note 6, at 4-11; see also Malinowski,
Market Implications, supra note 3.
44. Health Insurance Portability and Accountability Act of 1996, Pub. L.
No. 104-191 (1996).
45. See supra note 2.
46. This legacy, in sum, is approximately three hundred million samples
that have been collected over the last century-the majority held by the U.S.
Government, mostly without disclosure and consent. See supra notes 28-31 and
accompanying text.
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complicated problems that come with this new generation of
human biological sample collection and use.47 In just a few
minutes, you will hear Robert Wells address related intellectual
property controversies. An aspect of that discussion is the
fundamental debate over whether there should be a quid pro quo
for use of one's human biological materials. Participation in
research generates the thought that, if possible, there should be a
return to subjects. In this area lies an intriguing set of questions,
and I am going to talk about them more in the group context.
Privacy and confidentiality, of course, are big issues. Re-
contacting donors-the whole idea of, if you are bringing people
into something to create a medical result, what do you owe these
donors? How far back do you go? What do you give them in
terms of an incentive to participate, a return on their participation?
Again, these are old issues that are innately tied to just using
biological samples in general.
There are some interesting angles introduced by contemporary
genomics and biobanking, such as the amount of samples you need
and what impact that has on the status of individual participants
and subject recruitment. You just heard what Iceland went through
with its recruiting process. Individual consent is a fundamental
bioethics consideration. Dr. Knoppers framed the issue last
night, and mentioned the ongoing controversy over whether
permissible consent for biobanking should be limited to use-
specific consent or expanded to include blanket consent and, if yes,
under what circumstances? 49 If you are creating a biobank, the
idea is that you want to build a resource that is going to have all
kinds of uses going forward, many yet undefined. So, blanket
consent becomes something that, presumably, is more appealing.
Also, because you are dealing with groups, the idea of group
consent sets in. Group consent is something that we really have
not dealt with very well or thoroughly in the past, but it is innate to
the biobanking approach. 50
47. See generally Regulation of Biobanks, supra note 1. See also
Malinowski, Population Health Futures, supra note 19, app. at 61 ("Select Law-
Policy Challenges for Biobanking").
48. See generally Ellen Wright Clayton, Informed Consent and Biobanks,
33 J.L. Med. & Ethics 15 (2005).
49. Bartha Maria Knoppers, Overview of Law and Policy Challenges, 66
La. L. Rev. (Special Issue) 21 (2006).
50. Greely, supra note 14.
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Another dimension of complexity is added by the global nature
of biobanking.5' We already have exported a lot of our clinical
research. The biomedical community's demand for clinical data is
immense, and many pharmaceutical and biotechnology companies,
directly and through contract research organizations (CROs), are
collecting that data outside of our borders.5 2 Well, now we are
beginning to do the same thing with samples-meaning going
outside the U.S. to collect them rigorously. We are doing so at a
time when the science gap between developed and developing
economies never has been wider, and the healthcare needs of
developing economies never have been greater. The result is a
looming question as to what humanitarian obligations are arising
and how we are going to meet them. 4
IV. USING PAST BIOTECH R&D EXPERIENCE TO SHAPE THE
FUTURE
If you look back at the evolution of contemporary commercial
biotechnology, there is behavior that readily distinguishes the
sector. The historically disjointed fundamental interests and
cultures of academia, industry, and government have integrated
through applied biotechnology. Also, while intensely dependent
on intellectual property, the biotechnology sector has and
51. See generally Bartha Maria Knoppers, Biobanking: International
Norms, 33 J.L. Med. & Ethics 7 (2005) [hereinafter Knoppers, Biobanking].
52. As of 2003, the contract research organization (CRO) sector was
conducting forty-percent more clinical trials overseas than it had in the past. See
C. Rowland, Clinical Trials Seen Shifting Overseas, Boston Globe, July 11,
2003, at Cl; see also Joseph A. DiMasi et al., The Price of Innovation: New
Estimates of Drug Development Costs, 22 J. Health Econ. 151 (2003), available
at http://www.cptech.org/ip/health/econ/dimasi2003.pdf; Tufts Center for the
Study of Drug Development, Backgrounder: How New Drugs Move through the
Development and Approval Process (Nov. 1, 2001), http://csdd.tufts.edu/
NewsEvents/RecentNews.asp?newsid+4; Malinowski, Population Health
Futures, supra note 19, app., nn. 146-54 and accompanying text.
53. Cf Jeffrey D. Sachs, The End of Poverty: Economic Possibilities For
Our Time (Penguin Press 2005).
54. Economist Jeffrey Sachs, head of Columbia's Earth Institute
(http://www.earthinstitute.columbia.edu) and the United Nation's Millennium
Development Project, has and continues to engage in considerable work
centered on this question. See generally Sachs, supra note 53.
55. See generally Michael J. Malinowski, Biotechnology: Law, Business,
and Regulation (Aspen 1999 & Supps. 2001, 2002, 2003, 2004).
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continues to evolve through collaboration among competitors,
56
albeit often built upon intellectual property rights and agreements.
Competitors have had to collaborate at an unprecedented level to
advance the science-to create shared resources beyond the means
of any one entity. When at a point where progress has run into
seemingly insurmountable obstacles, competitors have come
together and collaborated, and scaled immense difficulties. HGP is
the most obvious example. 57 Beyond HGP, we have had formation
of the Single Nucleotide Polymorphisms ("SNP") Consortium,5
8
the objective of which is to identify connections between slight
genetic variations and human health, and many other group
efforts-for example, the clinical trials coalition shaped in
California. 59 It is interesting that the small business model has
56. If you look at the fundamental founding of the economic side, where did
biotech take root? The answer is in Cambridge, Massachusetts and the San
Francisco Bay area-regions where competitors came together and they, in
collaboration, responded to legislative questions, including tax issues, and
developed favorable laws and policies to build and maintain environments
hospitable to them. On the science side, again, the same has been true and on a
whole other level-for example, HGP.
57. See supra note 8 and accompanying text.
58. The SNP Consortium draws together pharmaceutical, biotech, and
academic participants-many market competitors in other contexts-with the
unified mission of identifying connections between variations of single letters in
the genetic code and human health characteristics, such as adverse drug
reactions. See The SNP Consortium, Ltd. Home Page, http://snp.cshl.org. The
entity at the center of the SNP Consortium is Orchid Biosciences, Inc., and
information about the effort is available at http://www.orchid.com.
59. Stanford, the University of California San Francisco, and the University
of California San Diego entered into a consortium with SRI International, a
nonprofit research institute, to reduce their clinical trial dependence on industry.
See Andrew Pollack, Three Universities Join Researcher to Develop Drugs,
N.Y. Times, July 31, 2003, at Cl, C2. The consortium, PharmaStart (also
known as the "West Coast Clinical Trial Initiative"), was inspired by the
reluctance of venture capitalists and pharmaceuticals to invest in the clinical
development of academic research-especially for rare diseases. Id. at C2.
Similarly, in the area of screening of potential drug targets with a focus on rare
diseases (e.g., Huntington's and amyotrophic lateral sclerosis), Harvard
University has established the Laboratory for Drug Discovery in
Neurodegeneration, and the City of Hope National Medical Center (Duarte, CA)
has established a factory "to make experimental drugs for use in clinical trials."
Id. Moreover,
Beyond academic centers, patient advocacy groups are also taking a
much more active role in sponsoring or doing research aimed at finding
cures for specific diseases. And nonprofit drug organizations, backed
BIOBANK
become so synonymous with a sector undertaking such enormous
scientific and commercial challenges. And a solid baseline of
collaboration has made that model work: clearly, there would be
no genomics revolution without HGP, and the SNP Consortium
has contributed to moving science to the point where we are
starting to make medical sense out of the genome.
60
I refer to these shared resources as "biocommons" to reflect
that they are a resource intentionally created through collaboration
because their existence, though in some instances essential to
advance science in a timely manner and recognized as such,
generally is beyond the resource means or economic incentives of
any one entity that directly benefits from their creation. As with
virtually all invention in the life sciences, intellectual property (IP)
rights generally are established in the construction of these
commons, but those rights do not necessarily conflict with access.
First, many of these resources would not be created, or at least not
with anything approaching the same timeliness, but for the
intellectual property rights that have become the norm in the
field-for academia and the government as well as industry. The
alternative, nonexistence, is the ultimate barrier to access-
meaning that the very existence of these commons increases the
potential of access significantly. Second, in some instances, these
commons have been built with the express intention of overcoming
IP impediments to access.
61
by contributions from philanthropists, have arisen to try to develop
drugs for diseases in developing countries, like malaria and
tuberculosis, which tend to be neglected by pharmaceutical companies.
Id.
60. See supra note 2.
61. For example, in July 2003, several leading universities announced that
they, with support from the Rockefeller Foundation and the McKnight
Foundation, have joined forces to share proprietary information on biotech crops
and to make their patented technologies available to feed potentially millions, if
not billions, of people now in need. See Andrew Pollack, Universities to Share
Patented Work on Crops, N.Y. Times, July 11, 2003, at A14 ("Saying the
development of crops that could feed millions of people is being choked off by
biotechnology patents held by large corporations, several leading universities are
joining to share information on their patented technologies and make them more
widely available."). Participants in this free exchange of seed and technology
that could improve crop breeding include Cornell University, the University of
California, the University of Florida, Michigan State University, Rutgers
University, and the University of Wisconsin. Id. The methodology includes
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So, we have to ask ourselves, given that we have seen these
collaborations take form in response to collective needs and
significant collective value added as a result, where is science's
clear collective need now? Making medical sense out of the
intricacies of the human genome, especially in the context of
environmental influences, is dependent upon access to voluminous
patient samples and medical histories. Biobanking is both
necessary and desirable if we are going to move biomedical
science forward towards improving human health in a rigorous
manner. Biobanking could also be a means to accomplish much
more. My background is biotech research and development
("R&D"), including economic incentive programs, and human
subject protections. If you pull that together and apply it to
biobanking, you see tremendous opportunity to do some real good
for groups and, perhaps, even whole countries that have been left
out of the genomics revolution.
Collectively, HGP, the SNPS Consortium, the Biotech Crop
Initiative, the West Coast Clinical Trial Collaboration, and the
PLoS effort illustrate that strong recognition of intellectual
property rights in invention and technology transfer are workable
even when objectives transcend economic return: they can be used
to create value that becomes a quid pro quo to advance research
reservation of some rights for humanitarian applications and pooling patents into
packages to reduce transaction costs for crop developers:
Corporations seeking to generate support for biotechnology have
become more willing to provide royalty-free licenses to their patents
for humanitarian purposes. The major companies agreed to cooperate
with the African Agricultural Technology Foundation, formed this year
by the Rockefeller Foundation to speed the transfer of biotechnology to
Africa..
Id. Another group of academics have joined forces to trump the commercial
copyright choke hold on breakthrough scientific information. This coalition, led
by Dr. Harold Varmus, former director of the National Institutes of Health,
seeks to create the Public Library of Science (PLoS) to overcome impediments
to distribution of knowledge attributable to cost of research publications. See
Editorial, Open Access to Scientific Research, N.Y. Times, Aug. 7, 2003, at
A22. The PLoS methodology is to establish a new series of peer-reviewed
journals that will be available on the Internet free of charge and that increase
dissemination of data about research. See Carey Goldberg, Scientists Seek Open
Access to Medical Research, Boston Globe, Aug. 14, 2003, at Al, A 17.
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and distributive justice-driven objectives. Already, case studies
demonstrate that the same can be accomplished in biobanking.
62
In the 1980s, it probably would have sounded "academic"-
certainly counter to the prevailing culture at the time-to many in
academia to propose that universities fully embrace interacting
with industry to the point of gaining access to their enabling
technologies and engaging them with commercial sophistication.
At that time, if you talked to some of the prestigious university
administrators and mentioned the concept of a technology transfer
office as aggressive and active as those we know today, you
probably would have been dismissed quickly, if not wholly
avoided.
We should approach biobanking with an open and thoughtful
mind. Our first priority should be to eliminate some standing
problems. Most notably, biobanking is a means to shift away from
using all of those hundreds of millions of samples that were
generally collected without consent-often without the patient's
knowledge.63 So, it is an alternative to doing something that, with
hindsight, we should not have been doing in the first place.
Biobanking also could be the means to bring in groups that have
been traditionally excluded from mutually beneficial participation
in biomedical research. Although Iceland was not a big participant
in the genomics revolution, it definitely has a role now.
64
Similarly, to include more African-Americans in studies, Howard
University has announced creating the largest biobank of African-
American samples.65
Another actual biobanking case study illustration of this point
is research into pseudoxanthoma elasticum ("PXE"), a rare,
hereditary connective tissue disorder that afflicts the skin and
eyes.66 Into the 1990s, very little meaningful research was being
done on PXE. There was no financial reason for anyone to do
research on the disease. The international patient and supporters
62. The case studies include the disease group PXE and Howard
University's biobanking initiative, which are discussed infra at notes 65-67 and
in the accompanying text.
63. See supra note 26 and accompanying text.
64. See supra notes 16-17 and accompanying text.
65.' Andrew Pollack, DNA of Blacks To Be Gathered To Fight Illness, N.Y.
Times, May 27, 2003, at Al, A20 [hereinafter Pollack, DNA]. This plan
consists of gathering DNA samples from 25,000 people over five years, drawing
mainly from patients at hospitals affiliated with the Howard College of
Medicine and using alumni to solicit donors globally. Id. at A20.
66. See the entry for "PXE" at the Cancer Web On-Line Medical
Dictionary, http://cancerweb.ncl.ac.uk/cgi-bin/omd?PXE.
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group decided to biobank, and they did so in a manner that holds
ownershiP over all that comes out of research using their
material. Nevertheless, subsequent to establishment of this bank
seventeen labs have taken on doing this research for this group.
69
The experience underscores that the means to do exciting research
has value, and there are excellent scientists who will be drawn to
opportunities to do their best work even if intellectual property
rights are forfeited.
Hospitals also are engaging in biobanking. Ardais Corporation
has a biobanking deal with the Harvard-affiliated Beth Israel
Deaconess Medical Center, the University of Chicago Medical
Center, Duke University Medical Center, and Maine Medical
Center.6 9  For these hospitals, the arrangement introduces a
67. The PXE case study is presented in Winickoff, supra note 7, at 223-25.
68. Id. at 224.
69. Beth Israel announced its biobanking effort with Ardais in September
2000, and the collaboration was subsequently expanded to include Duke
University Medical Center, Maine Medical Center, and the University of
Chicago. See Press Release, Ardais Biospecimen Management System and
Software, Ardais Corporation and Leading Medical Centers Launch Initiative to
Accelerate Genomics-Based Drug Discovery (Sept. 1, 2000)
http://www.ardais.com/news-events/press-releases.shtml. Ardais is a private
company based in Lexington, MA. See The Ardais Corporation Home Page,
http://www.ardais.com. Ardais' growing collection exceeds 160,000 samples
and is attracting significant users, such as Xantos Biomedicine AG of Munich,
which is using Ardais' bank "to validate drug targets in inflammatory and
degenerative diseases." Jeffrey Krasner, Study By Tufts Group Says Average
Cost of a Drug's Development is $897M, Boston Globe, May 14, 2003, at C4.
Ardais is representative of an emerging biobanking commercial sector. This
sector includes The First Genetic Trust ("First Genetic"), located in Chicago,
Illinois, and Genomics Collaborative, Inc. in the Boston area. See First Genetic
Trust Homepage, http://www.firstgenetic.net and Genomics Collaborative, Inc.
Homepage, http://www.genomicsinc.com/index.html. Like Ardais, First
Genetic collects and organizes genetic information while concealing patients'
identities, and one of First Genetic's ongoing projects is to create the GRAD
Biobank to research in the African diaspora. See First Genetic Trust
Homepage, http://www.firstgenetic.net; Pollack, DNA, supra note 65, at A20.
Similarly, Genomics Collaborative, Inc. is building a global repository of tissue
and white blood cell samples. See Jeffrey Krasner, Gene Pooling: Company
Builds World's Largest Library of Genetic Material, Boston Globe, Aug. 22,
2001, at Fl, F4. The company creates serum by removing all cells from blood
samples, which it freezes at minus eighty degrees Celsius, and stores the tissue
and white blood cell samples at minus 160 degrees Celsius in liquid nitrogen.
See id
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revenue source and research opportunities. 7  Consider the
potential benefits of biobanking for Louisiana's Charity Hospital
system, which, at least prior to the dual blows of Katrina and Rita,
was large, had tremendous financial need, and encompassed
significant patient populations desirable for research in diabetes,
sickle cell anemia, and heart disease.
71
Beyond actual biobanking case studies, there is ample life
science technology transfer and development experience and many
experience-based models to draw from to advance responsible
biobanking. The challenge is to be innovative and actually use and
apply-to think creatively, constructively, and to develop
biobanking implementations. That said, the challenge is
considerable, for the ethical, legal, and social implications of
biobanking must be addressed thoughtfully at the outset of any
biobanking undertaking. As you will hear during the HapMap
discussions, population genetics already has created some identity
confusion. We are learning to appreciate the extent to which
genetics does not necessarily follow the lines-race, culture, and
so forth-by which we as societies define ourselves. The
experience of the Seminole Indians with genetics and group
identity makes this point.73 More than a century of group identity
based upon culture was trumped by tribal leaders wanting to "thin
the herd" through biology to centralize distribution of government
reparations money.
"4
The sample and medical information needs of the research
community, the human health potential of that research, and the
opportunity to work on a group level create an atmosphere of
heightened temptation to sacrifice the individual for research.
Whether driven by the passion of research or commercial
applications and profits, that temptation rises with the potential of
R&D returns and meaningful human health applications.
Conceptually, from a regulatory perspective, how should
biobanking be approached? Does it simply fold into existing
research-related regulations? Should we distinguish biobanking
70. Winickoff, supra note 7, at 223-25.
71. Jan Moller, Charity Hospital Gets Emergency Cash Money Will Keep
Three Clinics Open, New Orleans Times Picayune, Feb. 21, 2004, available at
2004 WLNR 1527426.
72. Ellen Wright Clayton, Implications for Existing Law/Regulations, 66
La. L. Rev. (Special Issue) 125 (2006).
73. See generally Carla D. Pratt, Tribes and Tribulations: Beyond Sovereign
Immunity and Toward Reparation and Reconciliation for the Estelusti, 11 Wash.
& Lee Race & Ethnic Anc. L.J. 61 (2005).
74. Id. at 130.
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from this context and, instead, approach biobankers as service
providers and, in addition to research regulations, regulate the
practice directly-perhaps in a manner that provides guidance and
incentives? In crafting such an approach, perhaps it would be
possible to draw from the established regulatory structure centered
on the goals of ensuring proficiency and reliability for commercial
laboratories through the Clinical Laboratory Improvement
Amendment (CLIA) regulations. 75  CLIA is essentially a
certification system to ensure satisfaction of. extensive technical
requirements that is largely carried out by accredited professional
organizations-ultimately meaning a combination of direct
government regulation and professional self-regulation, but with an
emphasis on government presence. Perhaps we should introduce
an analogous certification system to ensure the proficiency,
reliability, and general regulatory compliance of biobanking
services? Another possible option would be to approach the
contents of biobanks as commercial products and regulate
biobanking more directly through the FDA.76 Or, to complete the
circle of possibilities, we could directly address biobanking, but in
the context of research regulations. These are widely varied
regulatory approaches, and all are just options and not necessarily
feasible or desirable. The point is that we have to figure out the
best regulatory approach to promote responsible biobanking if we
are going to stimulate the activity aggressively-which is both
desirable and probable given the present needs of the biomedical
research community.
77
At the very least, serious consideration should be given to
reinforcing the baseline for protection of human subjects in the
context of biobanking. For years, especially during the genomics
revolution and aggressive commercialization of biomedical R&D,
the possibility of expanding the Common Rule,78 the regulations to
protect human subjects in research, has been rigorously
75. 42 C.F.R. §§ 493.1, 493.3, 493.5, 493.15, 493.17, 493.19, 493.20,
493.25, 493.35, 493.37, 493.39, 493.45, 493.47, 493.49, 493.51,493.53 (1996).
76. If such an approach were adopted, perhaps we could draw from the
FDA's recent experience generating new tissue product regulations? See
Human Cells, Tissues, and Cellular and Tissue-Based Products, 66 Fed. Reg.
5447-01 (Jan. 19, 2001) (to be codified at 21 CFR pts. 207, 807). See generally
FDA Improves the Safety of Human Cells and Tissues by Finalizing New Rules
for "Good Tissue Practice," U.S. Food and Drug Administration, Nov. 18, 2004,
http://www.fda.gov/bbs/topics/news/2004/NEW01137.html. For more infor-
mation, visit http://www.fda.gov/cber/tissue/docs.htm.
77. See infra note 93 and accompanying text.
78. 45 C.F.R. §§ 46.101-46.124 (2005).
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contemplated. 79 A common denominator among these proposals is
to pull in some research done with private money and without a
FDA product application-meaning research that presently escapes
the reach of human subject protection regulations. °
Biobanking is commerce, and even small efforts-consider the
PXE case study8 '--often embody a global element reflective of the
nature of genomics research. Perhaps biobanking is the research
application where we expand the Common Rule to include all
research on human subjects? Doing so would mean subjecting all
biobanking to institutional review board ("IMB") oversight, which
would further overwhelm that taxed system.82  Nevertheless, we
have some mechanisms for applying the Common Rule with
efficiency-namely exceptions and waivers (carve-outs) that we
already are using where the risk to the individual is low.83 In most
instances, biobanking will pose a low risk to individual subjects.
The scale of biobanking places one sample among thousands. The
informatics means to generate and process data through biobanking
offers assurance that the capabilities to ensure accountability and
to protect group and individual interests in biobanking do exist.
In closing, I look to our HapMap discussion with great
enthusiasm.8 4  The project is an experiment to Vrobe "proof of,, "85
principle" in population genetics based upon race. Regardless of
whether the underlying science theory is proven or refuted, the
project has already revealed immense ethical, legal, and social
issues which must be considered in all population genetics
research. Two of the principals in this aspect of the project are
79. See, e.g., National Bioethics Advisory Commission (NBAC), Research
Involving Human Biological Materials: Ethical Issues and Policy Guidance
(1999), http://www.georgetown.edu/research/nrcbl/nbac/hbm.pdf; Helena Gail
Rubinstein, If I Am Only for Myself What Am I? A Communitarian Look at the
Privacy Stalemate, 25 Am. J.L. & Med. 203, 221-22 (1999).
80. Michael J. Malinowski, Commercialization of Genetic Testing Services:
The FDA, Market Forces, and Biological Tarot Cards, 71 Tul. L. Rev. 1211,
1214-15 (1997).
81. See supra notes 66-67 and accompanying text.
82. See 45 C.F.R. §§ 46.102(g), 46.103(b)(4), 46.103(b)(5), 46.108(a)
(2005). See also 21 C.F.R. § 50.3(i) (2005).
83. See generally PricewaterhouseCoopers LLP, Institutional Review Board
(IRB) Reference Book 11 (Michele K. Russell-Einhorn & Thomas Puglisi eds.,
2001).
84. See generally Clayton, supra note 72 and accompanying text; see also
International HapMap Project Home Page, http://www.hapmap.org.
85. See generally Clayton, supra note 72.
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participating in this conference, Drs. Bartha Knoppers and Ellen
Wright Clayton.
We must draw from the experience and knowledge generated
through the HapMap project and biobanking case studies, and
make a serious effort to move forward ahead of market demand for
biobanking. For example, the World Health Organization
("WHO") is focusing on some serious epidemiological problems-
including AIDS and tuberculosis.86 Perhaps we could create an
incentive program through the World Bank, World Trade
Organization and/or UNESCO to do some desired biobanking that
helps with those disease groups, and do it in, again, a prototype
model-setting way?
We also must develop more international consistency and
guidance for potential biobankers on issues such as informed
consent and group consent. 87 We have done a good job in recent
years recognizing the global nature of biomedical research and
creating more common denominators and consistency, especially
in the area of clinical data acceptance through efforts like the
International Conference on Harmonisation ("ICH").88 Work is
well underway to establish more international guidance in the basic
research context essential for biobanking.8 9 Over just the last few
years, the United Nations Educational, Scientific, and Cultural
Organization ("UNESCO") issued an International Declaration on
Human Genetic Data,90 the Council for International Organizations
of Medical Sciences ("CIOMS") put forth ethical guidelines for
biomedical research,9' and the World Health Organization
("WHO") compiled a report on genetic databases.92  Hopefully
86. See World Health Organization, HIV Infections, http://www
.who.int/topics/hiv infections/en/; World Health Organization, Tuberculosis,
http://www.who.int/topics/tuberculosis/en/.
87. See Knoppers, Biobanking, supra note 51.
88. See generally J. John Lee, What is Past is Prologue: The International
Conference on Harmonization and Lessons Learned from European Drug
Regulations Harmonization, 26 U. Pa. J. Int'l Econ. L. 151 (2005).
89. See generally Knoppers, Biobanking, supra note 51.
90. UNESCO, International Declaration on Human Genetic Data (Oct. 16,
2003), available at http://portal.unesco.org/shs/en/filedownload.php/6016a
4bea4c293 a23e913de638045ea9Declarationen.pdf.
91. CIOMS, International Ethical Guidelines for Biomedical Research
Involving Human Subjects (2002), http://www.cioms.ch/frameguidelines_
nov_2002.htm.
92. World Health Organization, European Partnership on Patients' Rights
and Citizens' Empowerment, Genetic Databases Assessing the Benefits and the
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these efforts, what is learned through pilot programs such as the
HapMap project, and thoughtful reflection on case study
experiences will integrate quickly into more international law-
policy consistency and pragmatic guidance.
V. CONCLUSION
Biobanking is necessary to meet the pressing needs of the
genomics research community. 93  Broad access to organized
samples and medical information made possible through
biobanking will accelerate translation of the map of the human
genome into medical meaning. So, to what extent could and
should governments and international organizations such as the
WHO, the World Bank, and UNESCO introduce incentives for
desirable, responsible biobanking? Should those incentives take
the form of grant funding similar to HGP, or commercial economic
incentives and programs such as those used by the U.S. to
aggressively stimulate the biotechnology sector? Could we draw
from the International Conference on Harmonization ("ICH")
experience to develop more international consistency on
fundamental issues such as informed consent and thereby lower the
transaction cost of, and encourage more, global biobanking? We
have much biotechnology technology transfer and development
experience to draw from. These and similar questions present an
opportunity to move science, medicine, and biobanking forward in
a responsible manner.
Impact on Human Rights and Patient Rights (2003), www.law.ed.ac.uk/
ahrb/publications/online/whofinalreport.rtf.
93. McGinnis, supra note 4.
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